Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Immunization against Glioblastoma.
Schijns VEJC, Pretto C, Strik AM, Gloudemans-Rijkers R, Deviller L, Pierre D, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FPK, Hofman FM, Chen TC, Zidovetzki R, Bota DA, Stathopoulos A. Schijns VEJC, et al. Among authors: stathopoulos a. Int J Mol Sci. 2018 Aug 27;19(9):2540. doi: 10.3390/ijms19092540. Int J Mol Sci. 2018. PMID: 30150597 Free PMC article. Review.
Therapeutic targeting of malignant glioma.
Alexandru-Abrams D, Jadus MR, Hsu FP, Stathopoulos A, Bota DA. Alexandru-Abrams D, et al. Among authors: stathopoulos a. Anticancer Agents Med Chem. 2014;14(8):1075-84. doi: 10.2174/1871520614666140825105145. Anticancer Agents Med Chem. 2014. PMID: 25175690 Review.
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.
Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. Schijns VE, et al. Among authors: stathopoulos a. Vaccine. 2015 May 28;33(23):2690-6. doi: 10.1016/j.vaccine.2015.03.095. Epub 2015 Apr 10. Vaccine. 2015. PMID: 25865468 Free PMC article.
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. Bota DA, et al. Among authors: stathopoulos a. CNS Oncol. 2018 Jul 1;7(3):CNS22. doi: 10.2217/cns-2018-0009. Epub 2018 Aug 29. CNS Oncol. 2018. PMID: 30157683 Free PMC article. Clinical Trial.
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide.
Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, Stathopoulos A. Bota DA, et al. Among authors: stathopoulos a. Front Oncol. 2022 Jun 28;12:934638. doi: 10.3389/fonc.2022.934638. eCollection 2022. Front Oncol. 2022. PMID: 35837107 Free PMC article.
115 results